Stifel Transfers Sage Therapeutics (SAGE), Maintains Buy
Tweet
Share
E-mail
Get Alerts SAGE Hot Sheet
Price: $8.68 --0%
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Stifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.
Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $145.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie
- AAC Technologies Holdings Inc. (2018:HK) (AACAY) PT Raised to HK$55.50 at Macquarie
- China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) PT Lowered to HK$31 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, New CoverageRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
